Rgnia Dermaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-07-2024
- Paid Up Capital ₹ 0.10 M
as on 07-07-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 53.64 M
as on 07-07-2024
- Revenue 26.10%
(FY 2021)
- Profit 30.57%
(FY 2021)
- Ebitda 25.19%
(FY 2021)
- Net Worth 356.99%
(FY 2021)
- Total Assets 45.47%
(FY 2021)
About Rgnia Dermaceuticals
The Corporate was formerly known as Ashmon Infotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.36 Cr.
Ram Gupta and Anuragini Gupta serve as directors at the Company.
- CIN/LLPIN
U24100DL2007PTC157576
- Company No.
157576
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Rgnia Dermaceuticals?
Board Members(2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ram Gupta | Director | 06-Feb-2014 | Current |
Anuragini Gupta | Director | 12-May-2014 | Current |
Financial Performance and Corporate Structure Insights of Rgnia Dermaceuticals.
Rgnia Dermaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 26.1% increase. The company also saw a substantial improvement in profitability, with a 30.57% increase in profit. The company's net worth Soared by an impressive increase of 356.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Rgnia Dermaceuticals?
In 2021, Rgnia Dermaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Paragon Beauty Garden Private Limited
Active 24 years 18 daysRam Gupta and Anuragini Gupta are mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Axis Bank Limited Creation Date: 22 Oct 2022 | ₹1.80 Cr | Open |
Hdfc Bank Limited Creation Date: 04 May 2022 | ₹0.64 M | Open |
Axis Bank Limited Creation Date: 29 May 2020 | ₹3.50 Cr | Open |
How Many Employees Work at Rgnia Dermaceuticals?
Unlock and access historical data on people associated with Rgnia Dermaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rgnia Dermaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rgnia Dermaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.